OR WAIT null SECS
In an agreement with MaaT Pharma, Skyepharma will build MaaT a dedicated 1500-m² microbiome ecosystem therapies manufacturing site.
MaaT Pharma, a clinical-stage biotechnology company, announced on Feb. 8, 2022 that it had come to an agreement with Skyepharma, a French contract manufacturing and development organization, to build a new manufacturing facility. Estimated to be operational by 2023, the facility is set to be France’s largest specialized manufacturing facility for ecosystem microbiome-based therapeutics, according to a company press release.
The new manufacturing site will initially be 1500 m², allowing MaaT to increase its manufacturing capacities ten-fold. The size can also be doubled to 3000 m², depending on MaaT’s manufacturing needs. The facility will be designed to produce MaaT03X, MaaT’s new generation of drug candidates that use its unique proprietary microbiome ecosystem co-fermentation technology.
The facility will also be designed to produce several thousand enema’s of MaaT’s lead candidate, MaaT013, which is designed for graft-versus-host disease. Additionally, the facility will be able to produce several hundreds of thousands of capsules of the company’s second drug candidate, MaaT033, which is designed to improve survival in patients receiving allogeneic stem cell transplantation.
"As we enter Phase [III] with our lead product, MaaT013, the agreement with Skyepharma will allow us to scale up manufacturing to meet product demands, including commercial launch. We can look forward to expanding our product portfolio for cancer patients with serenity," said Hervé Affagard, co-founder and CEO of MaaT Pharma, in the press release. "This partnership is fully in line with France's ambition, as stated in the 2030 innovation plan for health, to become a nation at the forefront of biotherapies and ensure health independence in biomanufacturing. The emerging microbiome industry could open up an opportunity to position France as a leader."
Source: MaaT Pharma